#Israel #Jerusalem #biotechnology #Pepticom #IL-17 Inhibitors

Pepticom's Series A1 Funding Success

Pepticom, an innovative company at the forefront of artificial intelligence-driven peptide-based therapeutics, has successfully completed its Series A1 funding round, securing an impressive $6.6 million. This funding round was primarily led by Japan Israel High Tech Ventures 2 LP and supported by existing investors, showcasing strong confidence in Pepticom's pioneering approach.

With this new financial backing, Pepticom aims to accelerate the development of its oral IL-17 inhibitor program. This initiative targets significant advancements in treatments for autoimmune diseases such as psoriasis and psoriatic arthritis. The company is working on two families of fully synthetic, small cyclic peptidomimetic inhibitors, which have displayed remarkable efficacy in targetting both IL-17A and IL-17F isoforms.

The unique compounds designed through Pepticom's cutting-edge technology leverage non-natural amino acids, exhibiting remarkable improvements in stability and half-life both in vitro and in vivo. This addresses the critical needs in treating complex diseases and reflects a major leap in therapeutic options for patients suffering from autoimmune disorders.

Pepticom's proprietary drug discovery platform relies on an innovative combination of advanced machine learning techniques and biochemistry, allowing them to design peptides that boast exceptional specificity and therapeutic potential. The platform's algorithm can manipulate over 600 building blocks of natural and non-natural amino acids, allowing the exploration of an almost infinite chemical space with over 10⁸⁰ potential peptide structures.

This capability to design and discover new peptidomimetic targets is a significant advantage over traditional therapeutic modalities, accelerating drug discovery and development. This means that Pepticom can potentially bring effective peptide therapies to market at a fraction of the time and investment required by conventional methods.

Immanuel Lerner, CEO and co-founder of Pepticom, expressed his enthusiasm for the successful funding round, stating, "This validates our pioneering approach to AI-driven peptide drug discovery. Our platform's design of novel oral IL-17 inhibitors in record time and cost demonstrates its transformative impact to redefine how precision peptide therapeutics are discovered and developed. This funding accelerates our mission to bring more effective, accessible treatments to patients across multiple therapeutic areas."

Pepticom is distinguished by its mission to reshape medicine by developing targeted therapies for serious diseases, particularly in the realm of autoimmune disorders. Its innovative methodology offers hope for new and improved treatment options in areas that have historically faced unmet medical needs.

In addition, the venture capital fund that led this funding round, Japan Israel High Tech Ventures 2 LP, has a specific focus on investing in Israeli technology companies. Since its establishment in 2022, the fund has backed 19 Israeli startups across diverse technological sectors. Eyal Agmoni, Chairman of Chartered Group, remarked, "This investment marks a pivotal milestone in our commitment to fostering groundbreaking technologies that address critical challenges in healthcare. Pepticom's pioneering approach aligns seamlessly with our vision of supporting transformative innovations."

Pepticom is not only making strides in biotechnology but is also at the forefront of integrating AI into the development of effective therapeutics, ensuring that complex biological challenges are met with innovative solutions. As it continues on this path, the industry watches with interest, anticipating the next breakthroughs in peptide therapeutics that could reshape the landscape of medical treatments.

For more information about Pepticom and its groundbreaking innovations, visit www.Pepticom.com.